Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) May 02, 2014

TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (PL2.002)

Aaron Miller, Jerry Wolinsky, Ludwig Kappos, Giancarlo Comi, Mark Freedman, Tomas Olsson, Jinjun Liang, Deborah Bauer, Myriam Benamor, Barbara Wamil, Philippe Truffinet, Paul O'Connor
First published April 9, 2014,
Aaron Miller
1The Corinne Goldsmith Dickinson Centre of Multiple Sclerosis Icahn School of Medicine at Mount Sinai New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry Wolinsky
7University of Texas Health Science Center at Houston Houston TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludwig Kappos
5Neurology and Department of Biomedicine University of Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Comi
9University Vita-Salute San Raffaele Milan Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Freedman
6University of Ottawa and the Ottawa Hospital Research Institute Ottawa ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Olsson
2Karolinska Institute Stockholm Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinjun Liang
3Sanofi Bridgewater NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Bauer
3Sanofi Bridgewater NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myriam Benamor
4Sanofi Chilly-Mazarin France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Wamil
3Sanofi Bridgewater NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Truffinet
4Sanofi Chilly-Mazarin France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul O'Connor
8University of Toronto Toronto ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (PL2.002)
Aaron Miller, Jerry Wolinsky, Ludwig Kappos, Giancarlo Comi, Mark Freedman, Tomas Olsson, Jinjun Liang, Deborah Bauer, Myriam Benamor, Barbara Wamil, Philippe Truffinet, Paul O'Connor
Neurology Apr 2014, 82 (10 Supplement) PL2.002;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: The phase 3 TOPIC study (NCT00622700) assessed the efficacy and safety of teriflunomide in patients with a first clinical episode consistent with multiple sclerosis (MS) and 蠅2 T2 lesions on MRI scan. BACKGROUND: Teriflunomide is an oral once-daily immunomodulator for relapsing-remitting forms of MS. Pivotal studies of teriflunomide in relapsing forms of MS (RMS; TEMSO:NCT00134563; TOWER:NCT00751881) showed consistent efficacy across key clinical and MRI (TEMSO only) measures, and a well-characterized safety profile. DESIGN/METHODS: TOPIC was a double-blind, placebo-controlled, parallel-group study. Patients were randomized to teriflunomide 14mg, teriflunomide 7mg, or placebo. The primary endpoint analysis was time to new clinical relapse (108-week probability of new clinical relapse also calculated), and the key secondary endpoint analysis was time to new clinical relapse or MRI lesion. Safety and tolerability were also assessed. RESULTS: Baseline characteristics were generally well balanced. Of the randomized population (n=618), 59.1% had monofocal lesion presentation and 31.4% had 蠅1 gadolinium-enhancing lesion. Median time since neurological event was 2 months. Compared with placebo, teriflunomide 14mg reduced risk of new clinical relapse by 42.6% (p=0.0087), and 108-week probability of new clinical relapse was 24.0% vs 35.9% for placebo. Teriflunomide 14mg also reduced risk of new clinical relapse or MRI lesion by 34.9% (p=0.0003). Teriflunomide 7mg reduced risk of new clinical relapse by 37.2% (p=0.0271) and risk of new clinical relapse or MRI lesion by 31.4% (p=0.0020). Occurrence of adverse events (AEs) was similar across groups and consistent with previous studies. AEs more common with teriflunomide included alanine aminotransferase increase, diarrhea, hair thinning, infection (urinary and respiratory tract), and paresthesia. CONCLUSIONS: Teriflunomide demonstrated efficacy in delaying a new clinical relapse in patients with a first clinical episode consistent with MS. Together with outcomes from TEMSO and TOWER, these findings support the beneficial effect of teriflunomide in patients with RMS early and later in their disease course, and across a range of disease activity. Study Supported by: Genzyme, a Sanofi company

Disclosure: Dr. Miller has received personal compensation for activities wtih Acorda Therapeutics, Biogen Idec, GlaxoSmithKline, Inc., Merck Serono, Novartis, Nuron Biotech, Ono Pharmaceutical, Genzyme/Sanofi, Questcor, and Accordant Health Services. Dr. Miller has received personal compensation in an editorial capacity for Continuum and Continuum Audio. Dr. Miller has received research support from Acorda, Biogen Idec, Genentech, Inc., Genzyme/Sanofi-Aventis, Novartis, Osmotica, and Roche. Dr. Wolinsky has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals Inc., Roche Diagnostics Corp., Novartis, XenoPort, RND, Genzyme Corp., and Athersys. Dr. Wolinsky has received royalty payments from the University of Texas. Dr. Wolinsky has received research support from National Institutes of Health, Sanofi-Aventis Pharmaceuticals Inc., and Genzyme Corp. Dr. Kappos has received personal compensation for activities with the University Hospital Basel. Dr. Kappos has received research support from the Swiss MS Society, Swiss National Research Foundation, the European Union, Gianni Rubatto Foundation, Novartis, and Roche Diagnostics Corp. Dr. Comi has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., Novartis, Merck Serono, Biogen Idec, Bayer Pharmaceuticals Corp., Teva Neuroscience, and Actellion. Dr. Freedman has received personal compensation for activities with Actelion, Bayer, Biogen Idec, EMD Canada, Genzyme Corporation, Novartis, Opexa, Teva Neuroscience, and Sanofi-Aventis Pharmaceuticals, Inc. Dr. Freedman has received research support from Bayer and Genzyme. Dr. Olsson has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., Merck Serono, and Biogen Idec. Dr. Olsson has received research support from Sanofi-Aventis Pharmaceuticals Inc., Merck Serono, and Biogen Idec. Dr. Liang has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc. as an employee. Dr. Bauer has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc. as an employee. Dr. Benamor has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc. as an employee. Dr. Wamil has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc. as an employee. Dr. Truffinet has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc. as an employee. Dr. O'Connor has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals Inc., Roche Diagnostics Corp., Novartis, Genentech Inc., EMD Serono, Biogen Idec, Bayer Pharmaceuticals Corp., Actelion, and Genzyme Corp. Dr. O'Connor has received research support from Teva Neuroscience, Sanofi-Aventis Pharmaceuticals Inc., Roche Diagnostics Corp., Novartis, Genmab, Genentech Inc., EMD Serono, Daiichi Pharmaceutical Corp., Cognosci, BioMS, Biogen Idec, Bayer Pharmaceuticals Corp., and Actelion.

Friday, May 2 2014, 12:00 pm-1:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise